ClinicalTrials.gg
CompletedNCT01732822EUCLIDUpdated Oct 30, 2017Results posted

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

A Phase 3 interventional study of Ticagrelor and Clopidogrel in Peripheral Artery Disease, sponsored by AstraZeneca. Completed at 778 sites in 28 countries. Open to participants aged 50 Years to 130 Years. Per ClinicalTrials.gov, last updated 2017-10-30.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13,885
Allocation
Randomized
Ages
50 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing ticagrelor in Peripheral Arterial Disease — 1 open to participants now, 2 under way, none of them phase 3. Ticagrelor · Peripheral Arterial Disease.

Enrollment
Largest of 10
13,885 · median 58
Started
2012
the only one that year
Phase 3
3 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
3 of 10
AstraZeneca

Among the 10 studies testing ticagrelor in Peripheral Arterial Disease, this one has the largest enrollment, is the only one that started in 2012, is one of 3 in phase 3, and was the 1st registered.

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

1 of the 10 studies testing ticagrelor in Peripheral Arterial Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 50 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ticagrelor in Peripheral Arterial Disease, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.

Read the detailed description

A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

03

Conditions studied

  • Peripheral Artery Disease

Keywords

  • Peripheral artery disease Atherothrombotic events Atherosclerosis
04

Who can participate

Ages eligible
50 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female patients 50 years old or older Symptomatic peripheral artery disease

Exclusion criteria

Exclusion Criteria:

  • Patients needing dual anti-platlet drug treatment before start of study Planned revascularisation or amputation
  • Patients with known bleeding disorders
  • Patients with a history of intracranial bleed
  • Patients considered to be at risk of bradycardic events unless already treated with a permanent pacemaker
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
13,885 participants (actual)

Study arms

  • Experimental
    Ticagrelor

    Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets

    Drug: Ticagrelor

  • Active comparator
    Clopidogrel

    Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets

    Drug: Clopidogrel

Interventions

  • Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets

    Also known as: Brilinta/Brilique

  • Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets

    Also known as: Plavix

06

What researchers measure

Primary outcomes

  1. Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke

    Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date)

    Time frame: From randomization to PACD, an average of 2.5 years

Secondary outcomes

  1. Composite of CV Death, MI, Ischemic Stroke, and ALI

    Participants with CV death, MI, ischemic stroke or acute limb ischemia (ALI). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)

    Time frame: From randomization to PACD, an average of 2.5 years

  2. CV Death

    Participants with CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)

    Time frame: From randomization to PACD, an average of 2.5 years

  3. MI

    Participants with MI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)

    Time frame: From randomization to PACD, an average of 2.5 years

  4. All-cause Mortality

    Participants with all-cause death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)

    Time frame: From randomization to PACD, an average of 2.5 years

  5. Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic)

    Participants with CV death, MI or all-cause stroke. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)

    Time frame: From randomization to PACD, an average of 2.5 years

  6. ALI

    Participants with ALI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)

    Time frame: From randomization to PACD, an average of 2.5 years

  7. Lower Extremity Revascularization

    Participants with lower extremity revascularization (LER). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)

    Time frame: From randomization to PACD, an average of 2.5 years

  8. Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other])

    Participants with any revascularization. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)

    Time frame: From randomization to PACD, an average of 2.5 years

Other outcomes

  1. Net Clinical Benefit (Composite of CV Death/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)

    Participants with CV death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)

    Time frame: From randomization to PACD, an average of 2.5 years

  2. Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)

    Participants with all-cause death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)

    Time frame: From randomization to PACD, an average of 2.5 years

  3. Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/Fatal Bleeding/Intracranial Bleeding)

    Participants with all-cause death, MI, ischemic stroke, ALI, major amputation, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)

    Time frame: From randomization to PACD, an average of 2.5 years

  4. Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/TIMI Major Bleeding)

    Participants with all-cause death, MI, ischemic stroke, ALI, major amputation or Thrombolysis in Myocardial Infarction (TIMI) major bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)

    Time frame: From randomization to PACD, an average of 2.5 years

  5. Non-CV Death

    Participants with non-CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, CV death)

    Time frame: From randomization to PACD, an average of 2.5 years

  6. Changes in Fontaine Stage

    Progression of the clinical/symptomatic status of the limb by changes in Fontaine stage. Stage I - Asymptomatic Stage IIa - Intermittent claudication after more than 200 meters of pain free walking Stage IIb - Intermittent claudication after less than 200 meters of walking Stage III - Rest pain Stage IV - Ischemic ulcers or gangrene

    Time frame: From randomization to PACD, an average of 2.5 years

  7. Changes in Rutherford Classification

    Progression of the clinical/symptomatic status of the limb by changes in Rutherford classification. Category 0 - Asymptomatic Category 1 - Mild claudication Category 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters. Category 3 - Severe claudication Category 4 - Rest pain Category 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Category 6 - Severe ischemic ulcers or frank gangrene

    Time frame: From randomization to PACD, an average of 2.5 years

  8. Change in ABI/TBI From Baseline

    Change in ankle brachial index (ABI) / toe brachial index (TBI). Ankle brachial index (ABI) is the ratio of blood pressures from the ankle and arm and is used for diagnosing peripheral arterial occlusive disease (PAOD): Normal: 1 to 1.29 Borderline: 0.91 to 0.99 Mild PAOD: 0.71 to 0.90 Medium severe PAOD: 0.41 to 0.7 Severe PAOD: \<0.4 Toe brachial index (TBI) is the ratio between the toe pressure and the higher brachial pressure, used for diagnosing PAOD when the ABI cannot be used: Normal: \>0.7 Mild: 0.5-0.7 Moderate: 0.35-0.5 Moderate-Severe: \<0.35 and toe pressure 40 mmHg Severe: \<0.35 and toe pressure \< 30 mmHg

    Time frame: From randomization to PACD, an average of 2.5 years

  9. Any Amputation Caused by PAD

    Participants with any amputation caused by peripheral arterial disease (PAD). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)

    Time frame: From randomization to PACD, an average of 2.5 years

  10. Major Amputation Caused by PAD

    Participants with major amputation caused by PAD. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)

    Time frame: From randomization to PACD, an average of 2.5 years

  11. CV-related Hospitalization

    Participants with hospitalization associated with CV death, hospitalization due to MI, ischemic stroke, lower extremity revascularization, major amputation due to PAD, transient ischemic attack (TIA), coronary revascularization or unstable angina. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)

    Time frame: From randomization to PACD, an average of 2.5 years

  12. TIMI Major Bleeding Events

    Participants with TIMI major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)

    Time frame: From the date of first dose and up to and including 7 days following the date of last dose of study drug

  13. TIMI Major or Minor Bleeding Events

    Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)

    Time frame: From the date of first dose and up to and including 7 days following the date of last dose of study drug

  14. PLATO Major Bleeding Events

    Participants with PLATO major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)

    Time frame: From the date of first dose and up to and including 7 days following the date of last dose of study drug

  15. Premature Permanent Discontinuation of Study Drug Due to Any Bleeding Event

    Participants with a permanent discontinuation of study drug due to any bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)

    Time frame: From the date of first dose and up to and including 7 days following the date of last dose of study drug

07

Results

Posted Oct 30, 2017

Participant flow

This study was conducted at 821 centres randomising patients across 28 countries. The first patient was enrolled on 04 December 2012. The last visit of the last patient took place on 26 September 2016. In total, 16237 patients were screened.

Participant flow — Overall Study
MilestoneTicagrelor 90 mg bdClopidogrel 75 mg od
Started69306955
Completed68076842
Not completed123113
Withdrew: Withdrawal by subject123113

Outcome measures

PrimaryComposite of Cardiovascular (CV) Death/MI/Ischemic Stroke

Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participants
Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke
ParticipantsTicagrelor 90 mg bdClopidogrel 75 mg od
Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke751740
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.650 (The hypothesis will be tested at the 4.94% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence will be used to address the issue of multiple testing) · Hazard ratio (hr): 1.02 · 95% CI 0.92 to 1.13
SecondaryComposite of CV Death, MI, Ischemic Stroke, and ALI

Participants with CV death, MI, ischemic stroke or acute limb ischemia (ALI). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
Composite of CV Death, MI, Ischemic Stroke, and ALI
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
Composite of CV Death, MI, Ischemic Stroke, and ALI839833
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.738 (The hypothesis will be tested at the 4.94% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence will be used to address the issue of multiple testing) · Hazard ratio (hr): 1.02 · 95% CI 0.92 to 1.12
SecondaryCV Death

Participants with CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
CV Death
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
CV Death363343
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.400 (The hypothesis will be tested at the 4.94% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence will be used to address the issue of multiple testing) · Hazard ratio (hr): 1.07 · 95% CI 0.92 to 1.23
SecondaryMI

Participants with MI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
MI
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
MI349334
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.482 (The hypothesis will be tested at the 4.94% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence will be used to address the issue of multiple testing) · Hazard ratio (hr): 1.06 · 95% CI 0.91 to 1.23
SecondaryAll-cause Mortality

Participants with all-cause death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
All-cause Mortality
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
All-cause Mortality628635
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.913 (The hypothesis will be tested at the 4.94% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence will be used to address the issue of multiple testing) · Hazard ratio (hr): 0.99 · 95% CI 0.89 to 1.11
SecondaryComposite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic)

Participants with CV death, MI or all-cause stroke. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic)
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic)766759
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.724 (The hypothesis will be tested at the 4.94% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence will be used to address the issue of multiple testing) · Hazard ratio (hr): 1.02 · 95% CI 0.92 to 1.13
SecondaryALI

Participants with ALI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
ALI
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
ALI117115
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.846 (The hypothesis will be tested at the 4.94% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence will be used to address the issue of multiple testing) · Hazard ratio (hr): 1.03 · 95% CI 0.79 to 1.33
SecondaryLower Extremity Revascularization

Participants with lower extremity revascularization (LER). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
Lower Extremity Revascularization
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
Lower Extremity Revascularization846892
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.298 (The hypothesis will be tested at the 4.94% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence will be used to address the issue of multiple testing) · Hazard ratio (hr): 0.95 · 95% CI 0.87 to 1.05
SecondaryAny Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other])

Participants with any revascularization. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other])
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other])12111250
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.462 (The hypothesis will be tested at the 4.94% two-sided significance level to account for the planned interim analysis with the overall type I error preserved at 5%. A hierarchical test sequence will be used to address the issue of multiple testing) · Hazard ratio (hr): 0.97 · 95% CI 0.90 to 1.05
Other pre-specifiedNet Clinical Benefit (Composite of CV Death/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)

Participants with CV death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
Net Clinical Benefit (Composite of CV Death/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
Net Clinical Benefit (Composite of CV Death/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)789786
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.793 · Hazard ratio (hr): 1.01 · 95% CI 0.92 to 1.12
Other pre-specifiedNet Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)

Participants with all-cause death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)983992
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 1.000 · Hazard ratio (hr): 1.00 · 95% CI 0.92 to 1.09
Other pre-specifiedNet Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/Fatal Bleeding/Intracranial Bleeding)

Participants with all-cause death, MI, ischemic stroke, ALI, major amputation, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/Fatal Bleeding/Intracranial Bleeding)
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/Fatal Bleeding/Intracranial Bleeding)11191140
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.829 · Hazard ratio (hr): 0.99 · 95% CI 0.91 to 1.08
Other pre-specifiedNet Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/TIMI Major Bleeding)

Participants with all-cause death, MI, ischemic stroke, ALI, major amputation or Thrombolysis in Myocardial Infarction (TIMI) major bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/TIMI Major Bleeding)
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/TIMI Major Bleeding)11831199
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.949 · Hazard ratio (hr): 1.00 · 95% CI 0.92 to 1.08
Other pre-specifiedNon-CV Death

Participants with non-CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, CV death)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
Non-CV Death
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
Non-CV Death250272
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.377 · Hazard ratio (hr): 0.93 · 95% CI 0.78 to 1.10
Other pre-specifiedChanges in Fontaine Stage

Progression of the clinical/symptomatic status of the limb by changes in Fontaine stage. Stage I - Asymptomatic Stage IIa - Intermittent claudication after more than 200 meters of pain free walking Stage IIb - Intermittent claudication after less than 200 meters of walking Stage III - Rest pain Stage IV - Ischemic ulcers or gangrene

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
Changes in Fontaine Stage
ParticipantTicagrelor - Stage ITicagrelor - Stage IIaTicagrelor - Stage IIbTicagrelor - Stage IIITicagrelor - Stage IVClopidogrel - Stage IClopidogrel - Stage IIaClopidogrel - Stage IIbClopidogrel - Stage IIIClopidogrel - Stage IV
Stage I - End of treatment77568317115267437231983319
Stage IIa - End of treatment2271948560412823019565573321
Stage IIb - End of treatment452694693919563114503815
Stage III - End of treatment72412317915232312
Stage IV - End of treatment7751134710513
Missing - End of treatment24874340359472507243706045
Other pre-specifiedChanges in Rutherford Classification

Progression of the clinical/symptomatic status of the limb by changes in Rutherford classification. Category 0 - Asymptomatic Category 1 - Mild claudication Category 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters. Category 3 - Severe claudication Category 4 - Rest pain Category 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Category 6 - Severe ischemic ulcers or frank gangrene

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
Changes in Rutherford Classification
ParticipantTicagrelor - Cat 0Ticagrelor - Stage IITicagrelor - Cat 3Ticagrelor - Cat 4Ticagrelor - Cat 5Ticagrelor - Cat 6Clopidogrel - Cat 0Clopidogrel - Cat 1/2Clopidogrel - Cat 3Clopidogrel - Cat 4Clopidogrel - Cat 5Clopidogrel - Cat 6
Category 0 - End of treatment7756831711523374372319833136
Category 1/2 - End of treatment227194856041235230195655733183
Category 3 - End of treatment45269469391365631145038123
Category 4 - End of treatment7241231439152323111
Category 5 - End of treatment54311102664121
Category 6 - End of treatment232002214100
Missing - End of treatment248743403593314250724370603411
Other pre-specifiedChange in ABI/TBI From Baseline

Change in ankle brachial index (ABI) / toe brachial index (TBI). Ankle brachial index (ABI) is the ratio of blood pressures from the ankle and arm and is used for diagnosing peripheral arterial occlusive disease (PAOD): Normal: 1 to 1.29 Borderline: 0.91 to 0.99 Mild PAOD: 0.71 to 0.90 Medium severe PAOD: 0.41 to 0.7 Severe PAOD: \<0.4 Toe brachial index (TBI) is the ratio between the toe pressure and the higher brachial pressure, used for diagnosing PAOD when the ABI cannot be used: Normal: \>0.7 Mild: 0.5-0.7 Moderate: 0.35-0.5 Moderate-Severe: \<0.35 and toe pressure 40 mmHg Severe: \<0.35 and toe pressure \< 30 mmHg

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Mean · Change in ABI/TBI
Change in ABI/TBI From Baseline
Change in ABI/TBITicagrelor 90 mg bdClopidogrel 75 mg od
ABI - 6 months N = 6184(Tica), 6319(Clopi)0.016 ± 0.1360.011 ± 0.134
ABI - End of treatment N = 4951(Tica), 5073(Clopi)0.022 ± 0.1670.016 ± 0.167
TBI - 6 months N = 55(Tica), 48(Clopi)0.050 ± 0.1320.036 ± 0.137
TBI - End of treatment N = 36(Tica), 21(Clopi)0.059 ± 0.115-0.065 ± 0.304
Other pre-specifiedAny Amputation Caused by PAD

Participants with any amputation caused by peripheral arterial disease (PAD). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
Any Amputation Caused by PAD
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
Any Amputation Caused by PAD179208
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.164 · Hazard ratio (hr): 0.87 · 95% CI 0.71 to 1.06
Other pre-specifiedMajor Amputation Caused by PAD

Participants with major amputation caused by PAD. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
Major Amputation Caused by PAD
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
Major Amputation Caused by PAD100116
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.306 · Hazard ratio (hr): 0.87 · 95% CI 0.67 to 1.14
Other pre-specifiedCV-related Hospitalization

Participants with hospitalization associated with CV death, hospitalization due to MI, ischemic stroke, lower extremity revascularization, major amputation due to PAD, transient ischemic attack (TIA), coronary revascularization or unstable angina. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)

Time frame:
From randomization to PACD, an average of 2.5 years
Reported as:
Number · Participant
CV-related Hospitalization
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
CV-related Hospitalization13121314
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.887 · Hazard ratio (hr): 1.01 · 95% CI 0.93 to 1.09
Other pre-specifiedTIMI Major Bleeding Events

Participants with TIMI major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)

Time frame:
From the date of first dose and up to and including 7 days following the date of last dose of study drug
Reported as:
Number · Participant
TIMI Major Bleeding Events
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
TIMI Major Bleeding Events113109
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.489 · Hazard ratio (hr): 1.10 · 95% CI 0.84 to 1.43
Other pre-specifiedTIMI Major or Minor Bleeding Events

Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)

Time frame:
From the date of first dose and up to and including 7 days following the date of last dose of study drug
Reported as:
Number · Participant
TIMI Major or Minor Bleeding Events
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
TIMI Major or Minor Bleeding Events193175
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.138 · Hazard ratio (hr): 1.17 · 95% CI 0.95 to 1.43
Other pre-specifiedPLATO Major Bleeding Events

Participants with PLATO major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)

Time frame:
From the date of first dose and up to and including 7 days following the date of last dose of study drug
Reported as:
Number · Participant
PLATO Major Bleeding Events
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
PLATO Major Bleeding Events206188
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = 0.139 · Hazard ratio (hr): 1.16 · 95% CI 0.95 to 1.41
Other pre-specifiedPremature Permanent Discontinuation of Study Drug Due to Any Bleeding Event

Participants with a permanent discontinuation of study drug due to any bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)

Time frame:
From the date of first dose and up to and including 7 days following the date of last dose of study drug
Reported as:
Number · Participant
Premature Permanent Discontinuation of Study Drug Due to Any Bleeding Event
ParticipantTicagrelor 90 mg bdClopidogrel 75 mg od
Premature Permanent Discontinuation of Study Drug Due to Any Bleeding Event168112
Statistical analysis
  • Ticagrelor 90 mg bd vs Clopidogrel 75 mg od · Regression, Cox · p = <0.001 · Hazard ratio (hr): 1.58 · 95% CI 1.24 to 2.00

Adverse events

Collected over On or after the date of first dose and up to and including 7 days following the date of last dose of study medication. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Clopidogrel 75mg od—1,788/6,932 (25.8%)989/6,932 (14.3%)
Ticagrelor 90mg bd—1,716/6,910 (24.8%)1,682/6,910 (24.3%)
Most frequent serious events
Showing 10 of 1,145
Most frequent serious events
EventClopidogrel 75mg odTicagrelor 90mg bd
PneumoniaInfections and infestations164/6932137/6910
Cardiac failure congestiveCardiac disorders88/693268/6910
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders71/693287/6910
Atrial fibrillationCardiac disorders67/693269/6910
Carotid artery stenosisNervous system disorders60/693256/6910
Acute kidney injuryRenal and urinary disorders32/693248/6910
OsteoarthritisMusculoskeletal and connective tissue disorders41/693240/6910
Urinary tract infectionInfections and infestations40/693232/6910
AnaemiaBlood and lymphatic system disorders38/693239/6910
Gastrointestinal haemorrhageGastrointestinal disorders38/693234/6910
Most frequent other events
Most frequent other events
EventClopidogrel 75mg odTicagrelor 90mg bd
HaemorrhageVascular disorders787/6932997/6910
DyspnoeaRespiratory, thoracic and mediastinal disorders264/6932817/6910

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ticagrelor 90mg bdClopidogrel 75mg odTotal
Age66.6 ± 8.466.5 ± 8.566.6 ± 8.4
Age, Customized
Age, Customized(Participants)Ticagrelor 90mg bdClopidogrel 75mg odTotal
<65 years290029855885
Between 65 and 75 years292528505775
>75 years110511202225
Sex: Female, Male
Sex: Female, Male(Participants)Ticagrelor 90mg bdClopidogrel 75mg odTotal
Female190819803888
Male502249759997
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ticagrelor 90mg bdClopidogrel 75mg odTotal
Hispanic Or Latino104610672113
Not Hispanic Or Latino5884588811772
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ticagrelor 90mg bdClopidogrel 75mg odTotal
American Indian Or Alaska Native6362125
Asian8248101634
Black Or African American280289569
Native Hawaiian Or Other Pacific Islander235
Other110132242
White5651565911310
08

Study locations

778 sites
  • Research Site
    Alexander City, Alabama 35010, United States
  • Research Site
    Auburn, Alabama 36830, United States
  • Research Site
    Birmingham, Alabama 35235, United States
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Mobile, Alabama 36604, United States
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Mobile, Alabama 36617, United States
  • Research Site
    Cottonwood, Arizona 86326, United States
  • Research Site
    Mesa, Arizona 85206, United States
  • Research Site
    Phoenix, Arizona 85006, United States
  • Research Site
    Phoenix, Arizona 85012, United States
  • Research Site
    Scottsdale, Arizona 85260, United States
  • Research Site
    Fort Smith, Arkansas 72901, United States
  • Research Site
    Jonesboro, Arkansas 72401, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Berkeley, California 94705, United States
  • Research Site
    Beverly Hills, California 90210, United States
  • Research Site
    Chula Vista, California 91911-1350, United States
  • Research Site
    El Cajon, California 92020, United States
  • Research Site
    Fresno, California 93721, United States
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    La Mesa, California 91942, United States
  • Research Site
    Laguna Hills, California 92653, United States
  • Research Site
    Long Beach, California 90822, United States
  • Research Site
    Mission Viejo, California 92691, United States
  • Research Site
    Moreno Valley, California 92553, United States
  • Research Site
    Northridge, California 91325-4139, United States
  • Research Site
    Oceanside, California 92056, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Palo Alto, California 94304-1290, United States
  • Research Site
    Sacramento, California 95816, United States
  • Research Site
    Sacramento, California 95817, United States
  • Research Site
    San Diego, California 92114, United States
  • Research Site
    San Diego, California 92120, United States
  • Research Site
    San Francisco, California 94143-0222, United States
  • Research Site
    Stockton, California 95210, United States
  • Research Site
    Torrance, California 90505-5073, United States
  • Research Site
    Torrance, California 90509, United States
  • Research Site
    Loveland, Colorado 80538, United States
  • Research Site
    Bridgeport, Connecticut 06610, United States
  • Research Site
    Guilford, Connecticut 06437, United States
  • Research Site
    Norwalk, Connecticut 06851, United States
  • Research Site
    Stamford, Connecticut 06905, United States
  • Research Site
    Trumbull, Connecticut 06611, United States
  • Research Site
    Newark, Delaware 19713, United States
  • Research Site
    Newark, Delaware 19718-0002, United States
  • Research Site
    Wilmington, Delaware 19803, United States
  • Research Site
    Washington, D.C., District of Columbia 20422, United States
  • Research Site
    Atlantis, Florida 33462, United States
  • Research Site
    Bradenton, Florida 34201, United States
  • Research Site
    Brandon, Florida 33511, United States
  • Research Site
    Brooksville, Florida 34601, United States
  • Research Site
    Clearwater, Florida 33756, United States
  • Research Site
    Daytona Beach, Florida 32114, United States
  • Research Site
    Daytona Beach, Florida 32117, United States
  • Research Site
    Fort Myers, Florida 33907, United States
  • Research Site
    Gainesville, Florida 32605, United States
  • Research Site
    Hudson, Florida 34667, United States
  • Research Site
    Jacksonville, Florida 32205, United States
  • Research Site
    Jacksonville, Florida 32207, United States
  • Research Site
    Jacksonville, Florida 32209, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Jacksonville, Florida 32258, United States
  • Research Site
    Largo, Florida 33777, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    Miami, Florida 33176, United States
  • Research Site
    Ocala, Florida 34471, United States
  • Research Site
    Orange Park, Florida 32003, United States
  • Research Site
    Palm Harbor, Florida 34684, United States
  • Research Site
    Pensacola, Florida 32501, United States
  • Research Site
    Plantation, Florida 33324, United States
  • Research Site
    Safety Harbor, Florida 34695, United States
  • Research Site
    Saint Petersburg, Florida 33701, United States
  • Research Site
    Saint Petersburg, Florida 33709, United States
  • Research Site
    Sarasota, Florida 34239, United States
  • Research Site
    Stuart, Florida 34996, United States
  • Research Site
    Tallahassee, Florida 32308, United States
  • Research Site
    Tampa, Florida 33606, United States
  • Research Site
    Tampa, Florida 33613, United States
  • Research Site
    Trinity, Florida 34655, United States
  • Research Site
    Vero Beach, Florida 32960, United States
  • Research Site
    Wellington, Florida 33449, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Atlanta, Georgia 30310, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Augusta, Georgia 30901, United States
  • Research Site
    Cumming, Georgia 30041, United States
  • Research Site
    Lithonia, Georgia 30058, United States
  • Research Site
    Macon, Georgia 31217, United States
  • Research Site
    Martinez, Georgia 30907, United States
  • Research Site
    Savannah, Georgia 31404, United States
  • Research Site
    Tucker, Georgia 30084, United States
  • Research Site
    Idaho Falls, Idaho 83404, United States
  • Research Site
    Arlington Heights, Illinois 60005, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Chicago, Illinois 60616, United States
  • Research Site
    Hinsdale, Illinois 60521, United States
  • Research Site
    Rock Island, Illinois 61201, United States
  • Research Site
    Rockford, Illinois 61108, United States

Showing the first 100 of 778 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Szarek M, Hess C, Patel MR, Jones WS, Berger JS, Baumgartner I, Katona B, Mahaffey KW, Norgren L, Blomster J, Rockhold FW, Hsia J, Fowkes FGR, Bonaca MP. Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. J Am Heart Assoc. 2022 Jun 7;11(11):e025504. doi: 10.1161/JAHA.122.025504. Epub 2022 May 27. PubMed 35621222 ↗
  • Govsyeyev N, Nehler MR, Low Wang CC, Kavanagh S, Hiatt WR, Long C, Jones WS, Fowkes FGR, Berger JS, Baumgartner I, Patel MR, Goodney PP, Beckman JA, Katona BG, Mahaffey KW, Blomster J, Norgren L, Bonaca MP. Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. J Vasc Surg. 2022 Feb;75(2):660-670.e3. doi: 10.1016/j.jvs.2021.08.096. Epub 2021 Sep 28. PubMed 34597783 ↗
  • Norgren L, North R, Baumgartner I, Berger JS, Blomster JI, Hiatt WR, Jones WS, Katona BG, Mahaffey KW, Mulder H, Patel MR, Rockhold FW, Fowkes FGR. World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial. Vasc Med. 2022 Feb;27(1):21-29. doi: 10.1177/1358863X211038620. Epub 2021 Sep 13. PubMed 34516308 ↗
  • Hiatt WR, Hess CN, Bonaca MP, Kavanagh S, Patel MR, Baumgartner I, Berger JS, Blomster JI, Jones WS, Katona BG, Mahaffey KW, Norgren L, Rockhold FW, Fowkes FGR. Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. Circ Cardiovasc Interv. 2021 Jul;14(7):e009871. doi: 10.1161/CIRCINTERVENTIONS.120.009871. Epub 2021 Jul 13. PubMed 34253048 ↗
  • Hsia J, Kavanagh ST, Hopley CW, Baumgartner I, Berger JS, Fowkes GR, Jones WS, Mahaffey KW, Norgren L, Patel MR, Rockhold F, Blomster J, Katona BG, Hiatt WR, Bonaca MP. Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial. Vasc Med. 2021 Dec;26(6):608-612. doi: 10.1177/1358863X211017641. Epub 2021 Jun 3. PubMed 34082620 ↗
  • Galani J, Mulder H, Rockhold FW, Weissler EH, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Hiatt WR, Katona BG, Norgren L, Mahaffey KW, Quint JK, Patel MR, Jones WS. Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. Int J Chron Obstruct Pulmon Dis. 2021 Mar 29;16:841-851. doi: 10.2147/COPD.S292978. eCollection 2021. PubMed 33824584 ↗
  • Kochar A, Mulder H, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Katona BG, Lopes RD, Al-Khalidi HR, Mahaffey KW, Norgren L, Hiatt WR, Patel MR, Jones WS. Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. Circ Cardiovasc Qual Outcomes. 2020 Nov;13(11):e006550. doi: 10.1161/CIRCOUTCOMES.120.006550. Epub 2020 Nov 12. PubMed 33176462 ↗
  • Gutierrez JA, Heizer GM, Jones WS, Rockhold FW, Mahaffey KW, Fowkes FGR, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster JI, Hiatt WR, Patel MR. CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. Am Heart J. 2020 Nov;229:118-120. doi: 10.1016/j.ahj.2020.07.017. Epub 2020 Aug 16. No abstract available. PubMed 32950849 ↗
  • Fudim M, Hopley CW, Huang Z, Kavanagh S, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Katona BG, Mahaffey KW, Norgren L, Ostrom C, Patel MR, Jones WS, Hiatt WR. Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID Trial. Circ Cardiovasc Qual Outcomes. 2020 Sep;13(9):e006512. doi: 10.1161/CIRCOUTCOMES.120.006512. Epub 2020 Aug 31. PubMed 32862697 ↗
  • Long CA, Mulder H, Fowkes FGR, Baumgartner I, Berger JS, Katona BG, Mahaffey KW, Norgren L, Blomster JI, Rockhold FW, Hiatt WR, Patel MR, Jones WS, Nehler MR. Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. Circ Cardiovasc Qual Outcomes. 2020 Jul;13(7):e006399. doi: 10.1161/CIRCOUTCOMES.119.006399. Epub 2020 Jul 3. PubMed 32615798 ↗
  • Haine A, Kavanagh S, Berger JS, Hess CN, Norgren L, Fowkes FGR, Katona BG, Mahaffey KW, Blomster JI, Patel MR, Jones WS, Rockhold FW, Hiatt WR, Baumgartner I; International Steering Committee and Investigators of the EUCLID Trial. Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease. J Am Coll Cardiol. 2020 Feb 18;75(6):608-617. doi: 10.1016/j.jacc.2019.11.057. PubMed 32057375 ↗
  • Ward R, Huang Z, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Katona BG, Mahaffey KW, Norgren L, Vemulapalli S, Povsic TJ, Mehta R, Hiatt WR, Patel MR, Jones WS. Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. Am Heart J. 2020 Feb;220:51-58. doi: 10.1016/j.ahj.2019.11.007. Epub 2019 Nov 18. PubMed 31783279 ↗
  • Hopley CW, Kavanagh S, Patel MR, Ostrom C, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Jones WS, Katona BG, Mahaffey KW, Norgren L, Rockhold FW, Hiatt WR. Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial. Vasc Med. 2019 Oct;24(5):422-430. doi: 10.1177/1358863X19864172. Epub 2019 Jul 24. PubMed 31339474 ↗
  • Hess CN, Huang Z, Patel MR, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Held P, Jones WS, Katona B, Mahaffey KW, Norgren L, Rockhold FW, Hiatt WR. Acute Limb Ischemia in Peripheral Artery Disease. Circulation. 2019 Aug 13;140(7):556-565. doi: 10.1161/CIRCULATIONAHA.119.039773. Epub 2019 Jun 26. PubMed 31238713 ↗
  • Kolls BJ, Sapp S, Rockhold FW, Jordan JD, Dombrowski KE, Fowkes FGR, Mahaffey KW, Berger JS, Katona BG, Blomster JI, Norgren L, Abramson BL, Leiva-Pons JL, Prieto JC, Sokurenko G, Hiatt WR, Jones WS, Patel MR. Stroke in Patients With Peripheral Artery Disease. Stroke. 2019 Jun;50(6):1356-1363. doi: 10.1161/STROKEAHA.118.023534. Epub 2019 May 16. PubMed 31092165 ↗
  • Low Wang CC, Blomster JI, Heizer G, Berger JS, Baumgartner I, Fowkes FGR, Held P, Katona BG, Norgren L, Jones WS, Lopes RD, Olin JW, Rockhold FW, Mahaffey KW, Patel MR, Hiatt WR; EUCLID Trial Executive Committee and Investigators. Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial. J Am Coll Cardiol. 2018 Dec 25;72(25):3274-3284. doi: 10.1016/j.jacc.2018.09.078. Erratum In: J Am Coll Cardiol. 2019 Jul 16;74(2):264-269. doi: 10.1016/j.jacc.2019.06.001. PubMed 30573030 ↗
  • Olivier CB, Mulder H, Hiatt WR, Jones WS, Fowkes FGR, Rockhold FW, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster J, Patel MR, Mahaffey KW. Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. JAMA Cardiol. 2019 Jan 1;4(1):7-15. doi: 10.1001/jamacardio.2018.4171. PubMed 30540355 ↗
  • Baumgartner I, Norgren L, Fowkes FGR, Mulder H, Patel MR, Berger JS, Jones WS, Rockhold FW, Katona BG, Mahaffey K, Hiatt WR; Executive Committee and Investigators of the EUCLID Trial. Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial. J Am Coll Cardiol. 2018 Oct 2;72(14):1563-1572. doi: 10.1016/j.jacc.2018.07.046. PubMed 30261955 ↗
  • Berger JS, Abramson BL, Lopes RD, Heizer G, Rockhold FW, Baumgartner I, Fowkes FGR, Held P, Katona BG, Norgren L, Jones WS, Millegard M, Blomster J, Reist C, Hiatt WR, Patel MR, Mahaffey KW. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vasc Med. 2018 Dec;23(6):523-530. doi: 10.1177/1358863X18775594. Epub 2018 Jul 11. PubMed 29992857 ↗
  • Norgren L, Patel MR, Hiatt WR, Wojdyla DM, Fowkes FGR, Baumgartner I, Mahaffey KW, Berger JS, Jones WS, Katona BG, Held P, Blomster JI, Rockhold FW, Bjorck M; EUCLID Steering Committee and Investigators. Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. Eur J Vasc Endovasc Surg. 2018 Jan;55(1):109-117. doi: 10.1016/j.ejvs.2017.11.006. Epub 2017 Dec 20. PubMed 29273390 ↗
  • Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegard M, Reist C, Patel MR; EUCLID Trial Steering Committee and Investigators. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med. 2017 Jan 5;376(1):32-40. doi: 10.1056/NEJMoa1611688. Epub 2016 Nov 13. PubMed 27959717 ↗
  • Jones WS, Baumgartner I, Hiatt WR, Heizer G, Conte MS, White CJ, Berger JS, Held P, Katona BG, Mahaffey KW, Norgren L, Blomster J, Millegard M, Reist C, Patel MR, Fowkes FG; International Steering Committee and Investigators of the EUCLID Trial. Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. Circulation. 2017 Jan 17;135(3):241-250. doi: 10.1161/CIRCULATIONAHA.116.025880. Epub 2016 Nov 13. PubMed 27840336 ↗
  • Held P, Himmelmann A, Ditmarsch M. Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program. Future Cardiol. 2016 Jul;12(4):405-18. doi: 10.2217/fca-2016-0028. Epub 2016 May 10. PubMed 27160944 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in Sep 2016, 45 months.

Results were first posted in Oct 2017, 1 year 1 month after primary completion.

Of 26 phase 3 interventional studies under Peripheral Arterial Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 58. This study's 45 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2012
First posted
Nov 26, 2012
StartActual
Dec 4, 2012
Primary completionActual
Sep 26, 2016
CompletionActual
Sep 26, 2016
Results first posted
Oct 30, 2017
Last update
Oct 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01732822
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 26, 2012
Start date
Dec 4, 2012
Primary completion
Sep 26, 2016
Completion
Sep 26, 2016
Results posted
Oct 30, 2017
Last update
Oct 30, 2017

Study contacts

William R Hiatt, MD
study chair · University of Colorado School of Medicine
Peter Held, MD
study director · AstraZeneca

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion